Alnylam Pharmaceuticals Inc., (ALNY) discovers, develops & commercializes therapeutics based on ribonucleic acid interference. It comes under Healthcare – Biotech sector & trades as “ALNY” ticker at Nasdaq.
As discussed in the last article, ALNY ended (4) pullback at $442.51 low & resume higher in (5). It favors rally in (5) towards $494.95 - $511.13 area as minimum extension to extend April cycle. It already reached the minimum level expected in last article, so chasing rally is risky now. But we like to buy the next correction in ((4)) at extreme area, when reach against April-2025 low.
ALNY - Elliott Wave Latest Weekly View: 
It ended ((I)) at $140 high since inception in June-2025 & ((II)) pullback at $31.38 low in October-2016. Above there, it is showing nest as the part of (III) of ((III)). It placed (I) of ((III)) at $153.99 high in March-2018 & (II) at $60.27 low in December-2018. Within (III), it placed I at $242.97 high in December-2022 as diagonal & II at $141.97 low in April-2024. It ended ((1)) at $212 high, ((2)) at $117.58 low, ((3)) at $236.80 high, ((4)) at $181.65 low & ((5)) at $242.97 high. It corrected II in zigzag correction ended at 0.50 Fibonacci retracement of I.
ALNY - Elliott Wave View From 9.08.2025: 
Above April-2024 low of II, it placed ((1)) of III at $304.39 high & ((2)) at $205.87 low on 4.07.2025 low. Currently, it favors rally in ((3)) of III & reached 1.618 Fib extension of ((1)). Yet, it expects small upside to finish it before correcting next in ((4)). Within ((3)), it placed (1) at $333.70 high, (2) at $309.57 low, (3) at $469.81 high, (4) at $442.51 low & favors rally in (5). It expects rally in (5) towards $494.95 - $511.13 area to finish ((3)) before correcting in ((4)). If it breaks above $511.13, then it can extend up to $570.76 to finish ((3)). Chasing longs can be risky now. But we like to buy the next correction in ((4)) in 3, 7 or 11 swings against 4.07.2025 low.
면책 조항: 본 게시글에 표현된 견해는 전적으로 작성자의 견해이며 Followme의 공식 입장을 대변하지 않습니다. Followme는 제공된 정보의 정확성, 완전성 또는 신뢰성에 대해 책임을 지지 않으며, 서면으로 명시적으로 언급되지 않는 한 해당 내용을 기반으로 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다.
